In-vivo Bioequivalence Study of Ranolazine 500 mg extended-release tablets (Arang Pharma, Iran)
Not Applicable
Recruiting
- Conditions
- This study is performed on healthy volunteers and drug concentration in plasma is determined..
- Registration Number
- IRCT20200105046010N103
- Lead Sponsor
- Arang Pharm Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28) kg/m^2
Informed consent
Informed consentAge (18-55 years old)
Exclusion Criteria
Nicotine consumption
historyCardiovascular disease
disease HistoryLiver and kidney disease
HistoryAlcohol and opioid addiction
Allergy reactions history to Linagliptin or Metformin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Ranolazine's modulation of late sodium current in healthy volunteers?
How does Arang Pharma's Ranolazine 500 mg ER compare to RANEXA® in pharmacokinetic parameters like AUC and Cmax?
Which biomarkers predict interindividual variability in Ranolazine plasma concentration among healthy subjects?
What adverse drug reactions are reported in extended-release Ranolazine trials and how are they managed?
Are there combination therapies involving Ranolazine and other antianginal agents for ischemic heart disease management?